Bruker Stock Forecast Highlights Biocrates Acquisition Impact on Life Sciences Tools Market (simplywall.st)

• Bruker completed acquisition of Biocrates Life Sciences AG, a metabolomics kit vendor, altering competitive landscape for metabolomics services.
• Analyst consensus projects Bruker annual earnings growth of 68.9% and revenue growth of 4.6% through 2028.
• Price targets adjusted downward due to helium cost headwinds and margin pressure; current consensus near $49.15.

"Simply Wall St analyst consensus projects Bruker Corporation (NASDAQ:BRKR) will achieve 68.9% annual earnings growth and 4.6% annual revenue growth through 2028, with EPS expected to grow 69.5% per year. The report notes Bruker's completed acquisition of Biocrates Life Sciences AG, a key metabolomics kit provider, which directly influences the competitive landscape for metabolomics service providers. Analysts have adjusted price targets amid helium cost headwinds and margin pressure, with a current consensus target of approximately $49.15."